ZTS

Zoetis is the first animal health company to issue Environmental, Social and Governance (ESG) Review based on leading sustainability frameworks.

In the current session, Zoetis Inc. (NYSE: ZTS) is trading at $165.76, after a 0.26% gain. Over the past month, the stock increased by 1.45%, and in the past year, by 39.66%. With performance like this, long-term shareholders optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently under from its 52 week high by 6.16%. The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E indicates that shareholders do not expect the stock to perform better in the future, and that the company is probably undervalued. It shows that shareholders are less than willing to pay a high share price, because they do not expect the company to exhibit growth, in terms of future earnings. View more earnings on ZTSDepending on the particular phase of a business cycle, some industries will perform better than others. Zoetis Inc. has a better P/E ratio of 47.61 than the aggregate P/E ratio of 35.46 of the Pharmaceuticals industry. Ideally, one might believe that Zoetis Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. There are many limitations to P/E ratio. It is sometimes difficult to determine the nature of the earnings makeup of a company. Shareholders might not get what they're looking for, from trailing earnings.See more from Benzinga * Click here for options trades from Benzinga * Stocks That Hit 52-Week Highs On Thursday * Stocks That Hit 52-Week Highs On Wednesday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Zoetis (ZTS) gets marketing authorization for Librela, for monthly alleviation of osteoarthritis pain in dogs.

Morgan Stanley maintains Zoetis (NYSE:ZTS) with a Equal-Weight and raises the price target from $167 to $174.

The European Commission approves Zoetis' (ZTS) once-per-month monoclonal antibody (mAb), Librela (bedinvetmab), for alleviation of osteoarthritis pain in dogs, by inhibiting nerve growth factor, a key player in osteoarthritis pain.The company says that

The first injectable monoclonal antibody authorized for alleviation of osteoarthritis pain in dogs Librela works differently from other pain medications, combining one month of pain control and increased mobility,

Zoetis has received European Commission Marketing Authorization for Librela (bedinvetmab) for alleviation of osteoarthritis (OA) pain in dogs

Zoetis Inc. (NYSE:ZTS) just released its quarterly report and things are looking bullish. It was overall a positive...